Cargando…
VKORC1 Pharmacogenetics and Pharmacoproteomics in Patients on Warfarin Anticoagulant Therapy: Transthyretin Precursor as a Potential Biomarker
BACKGROUND: Recognizing specific protein changes in response to drug administration in humans has the potential for the development of personalized medicine. Such changes can be identified by pharmacoproteomics approach based on proteomic technologies. It can also be helpful in matching a particular...
Autores principales: | Saminathan, Ramasamy, Bai, Jing, Sadrolodabaee, Laleh, Karthik, Govindasamy Muralidharan, Singh, Onkar, Subramaniyan, Koilan, Ching, Chi Bun, Chen, Wei Ning, Chowbay, Balram |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001467/ https://www.ncbi.nlm.nih.gov/pubmed/21179214 http://dx.doi.org/10.1371/journal.pone.0015064 |
Ejemplares similares
-
The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
por: Al Ammari, Maha, et al.
Publicado: (2020) -
Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018) -
Metabolic profiling of HepG2 cells incubated with S(−) and R(+) enantiomers of anti-coagulating drug warfarin
por: Bai, Jing, et al.
Publicado: (2010) -
Precision medicine: from pharmacogenomics to pharmacoproteomics
por: Chambliss, Allison B., et al.
Publicado: (2016) -
VKORC1 variants as significant predictors of warfarin dose in Emiratis
por: Al-Mahayri, Zeina N, et al.
Publicado: (2019)